DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Office of Infectious Diseases, (BSC, OID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Time and Date: 8:30 a.m.–5 p.m., December 6, 2010.

Place: CDC, Global Communications Center, 1600 Clifton Road, NE., Building 19, Auditorium B1–B2, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The BSC, OID, provides advice and guidance to the Secretary, Department of Health and Human Services; the Director, CDC, the Director, OID; and the Directors of the National Center for Immunization and Respiratory Diseases, the National Center for Emerging and Zoonotic Infectious Diseases, and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, in the following areas: strategies, goals, and priorities for programs; research within the national centers; and overall strategic direction and focus of OID and the national centers.

Matters to be Discussed: The agenda will include OID and center updates, followed by a focused discussion to solicit recommendations from the board on a strategic document designed to increase the public health impact of CDC’s infectious disease prevention and control efforts.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information:
Robin Moseley, M.A.T., Designated Federal Officer, OID, CDC, 1600 Clifton Road, NE., Mailstop D10, Atlanta, Georgia 30333.
Telephone: (404)639–4461.

The Director, Management Analysis and Services office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: November 4, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

FOR FURTHER INFORMATION CONTACT:
BioLabs to exempt from the requirements of the NIH Guidelines research with certain plasmids when performed in K. lactis. In order for a broad class of research to qualify for exemption, it must be determined by the NIH Director that the research does not pose a significant risk to human health or the environment (Section III–F–6). One way to exempt a broad class of research from the requirements of the NIH Guidelines is to perform the research in specific certified host-vector systems (as outlined in Appendix C of the NIH Guidelines). Currently research with only three certified host-vector systems is exempt from the NIH Guidelines. These three certified systems are based upon two bacterial genera: *Escherichia* (*E. coli* K–12) and *Bacillus* (*B. subtilis* or *B. licheniformis*) and one lower eukaryotic genus: *Saccharomyces* (*S. cerevisiae* or *S. uvarum*). In order to certify a new host-vector system, data as outlined in Appendix I–II–B of the NIH Guidelines must be submitted for review.

Specifically, this application will be considered under Appendix I–II–B–1 (Host-Vector 1 Systems Other than *Escherichia coli* K–12). Data to be considered include: (i) The strain’s natural habitat and growth requirements; its physiological properties, particularly those related to its reproduction, survival, and the mechanisms by which it exchanges genetic information; the range of organisms with which this organism normally exchanges genetic information and the type of information that is exchanged; and any relevant information about its pathogenicity or toxicity; (ii) a description of the history of the particular strains and vectors to be used, including data on any mutations which render this organism less able to survive or transmit genetic information; and (iii) a general description of the range of experiments contemplated with emphasis on the...